Q1. Is an IHC panel including p53, Ki67, RB1 and/or p16 useful in differentiating NEC from G3 NET?
— Pancreatobiliary Pathology Society (@pbpath) March 14, 2024
Q2. When a tumor with NET G1 or G2 morphology harbors a TP53 or RB1 mutation (e.g., due to radiation or chemotherapy), what should we call this tumor?
— Pancreatobiliary Pathology Society (@pbpath) March 14, 2024
Q3. Which tissue based biomarker should be examined as predictive survival marker for PanNET other than Ki67:
— Pancreatobiliary Pathology Society (@pbpath) March 18, 2024
Q4. The current definition of MiNEN requires that at least 30% of each component be confirmed, but can a different cutoff (such as 10%) be accepted ?
— Pancreatobiliary Pathology Society (@pbpath) March 18, 2024
Q5. Which of the following cytological features have a prognostic significance?
— Pancreatobiliary Pathology Society (@pbpath) March 18, 2024
Hope you all are enjoying the feast of interesting teasers from our speakers! Join us on Sun, 3/24 #PBPS companion meeting! @TheUSCAP #USCAP2024
— Pancreatobiliary Pathology Society (@pbpath) March 20, 2024
Here's one more –
Q6. Which of the following morphologic variants of well diff NETs is associated with more aggressive behavior?
